RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of DX-8951f in treating women who have advanced or recurrent cancer of the cervix.
OBJECTIVES: * Determine the antitumor activity of DX-8951f in women with advanced or recurrent squamous cell carcinoma of the cervix. * Evaluate the quantitative and qualitative toxic effects of this regimen in these patients. * Evaluate the pharmacokinetics of this regimen in these patients. OUTLINE: This is a multicenter study. Patients receive DX-8951f IV over 30 minutes daily for 5 days. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months until death. PROJECTED ACCRUAL: Approximately 37 patients will be accrued for this study.
Study Type
INTERVENTIONAL
Purpose
TREATMENT
St. Luke's-Roosevelt Hospital
New York, New York, United States
Albert Einstein Clinical Cancer Center
The Bronx, New York, United States
Ruppert Health Center
Toledo, Ohio, United States
Brookview Research, Inc.
Nashville, Tennessee, United States
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Texas Oncology PA (TOPA) at Baylor-Sammons
Dallas, Texas, United States
University of Texas - MD Anderson Cancer Center
Houston, Texas, United States